EOLS · Evolus, Inc.
$6.22
+0.04 (+0.65%)
At close · Jul 28
Market Cap
$409.62M
Shares
65.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.22
Open$6.21
Day$6.09–6.41
52W$3.86–9.72
Avg vol 30d756K
Short int5.9M · 9.0% float · 7.3d
Short vol50%
Last earningsAug 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 4
Up next
Next earnings call
Aug 5, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
−4%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+27%
trailing
YTD return
−6%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
26 of 148 funds reported for Jun 30 · net +463.7K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.97% of float · ▼ -1.9% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
148 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
66%
contracting
EPS growth
+1%
Y/Y
Free cash flow
$-45.7M
Balance sheet
$19.7M
net debt
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 4, 2026
Total net revenues
· full-year 2026
Initiated
$327M – $337M
prior FY $297.18M
midpoint +11.7% Y/Y
Adjusted gross profit margin
· full-year 2026
Non-GAAP
Initiated
65.5% – 67%
Non-GAAP operating expenses
· full-year 2026
Non-GAAP
Initiated
$210M – $216M
Evolysse® and Estyme® injectable HA gels revenue contribution as
· full-year 2026
Initiated
10% – 12%
Guided vs delivered
· last 1 settled
Revenue
2025
guided $295M – $305M
$297.18M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
26 of 148 funds reported for Jun 30 · net +463.7K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.97% of float · ▼ -1.9% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
148 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $6 · 40%
52-wk high $10
vs 200-day avg +6%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $0.6M | first quarter of 2026 | — |
| Customer reorder rates | 71% | first quarter of 2026 | — |
| Customers purchasing Evolysse® | 3,500 | first quarter of 2026 | — |
| Evolus Rewards™ members increase vs first quarter of 2025 | 27% | first quarter of 2026 | — |
| Members in the Evolus Rewards™ consumer loyalty program grew during the quarter | 75,000 | first quarter of 2026 | — |
| Non-GAAP operating expenses non-GAAP | $49.1M | first quarter of 2026 | — |
| Repeat treatment rate for existing patients | 70% | first quarter of 2026 | — |
| Total customers since launch | 18,100 | first quarter of 2026 | — |
| Total purchasing accounts increased | 500 | first quarter of 2026 | — |
| U.S. account penetration | 60% | first quarter of 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EOLS
this stock
Evolus, Inc.
|
$409.62M | -6.5% | +36.0% | — | 9.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.03B | +12.4% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$50.49B | +4.5% | — | — | 0.0% |
|
HLN
Haleon plc
|
$45.23B | +1.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EOLS | +12.2% | -12.8% | +26.7% | -10.4% | -6.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +13.2% | -12.7% | +19.2% | -9.6% | -15.1% |
Key facts
CIK
1570562
CUSIP
30052C107
13F (30d)
23 filings
23 filers
Visit website
Investor relations